Skip to main content

Table 2 Cox proportional hazard analyzes for PFS after CBZ treatment

From: The efficacy and toxicity of cabazitaxel for treatment of docetaxel-resistant prostate cancer correlating with the initial doses in Japanese patients

  Univariate Multivariate
  Odds ratio (95% CI) P Odds ratio (95% CI) P
Age (y) > 70 0.90 (0.60–1.35) 0.617   
PS ≥ 1 1.04 (0.69–1.56) 0.864   
GS ≥ 9 1.00 (0.65–1.53) 0.982   
PSA (ng/ml) > 100 0.93 (0.62–1.41) 0.743   
Hb (g/dl) < 12 1.245 (0.828–1.871) 0.292   
LDH (U/L) > 300 1.28 (0.81–2.02) 0.298   
ALP (U/L) > 350 0.93 (0.62–1.40) 0.739   
Bone meta at diagnosis 1.55 (1.03–2.34) 0.037* 1.03 (1.03–2.37) 0.037*
Time to CRPC (y) < 1 1.19 (0.79–1.79) 0.4   
DTX cycle< 10 1.40 (0.92–2.13) 0.121   
ABI or ENZA 0.73 (0.45–1.17) 0.184   
Low initial CBZ dose 1.03 (0.67–1.58) 0.905 0.95 (0.62–1.47) 0.832
RDI 60% or lower 0.86 (0.54–1.39) 0.545   
  1. PS performance status, DTX docetaxel, ABI abiraterone, ENZ enzalutamide
  2. RDI relative dose intensity, *P < 0.05